Quick Answer
Protalix BioTherapeutics, Inc. reported Stockholders Equity of $48.23 million for the year ending 2025.
- Protalix BioTherapeutics, Inc. showed an increase of +11.6% in Stockholders Equity from 2024 to 2025.
- This data is from Protalix BioTherapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 18, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2014: -$55.60 million | Q1 2015: -$61.15 million | Q2 2015: -$65.14 million | Q3 2015: -$68.51 million | Q1 2016: $2.65 million | Q2 2016: -$7.98 million | Q3 2016: -$15.10 million | Q1 2017: -$68.47 million | Q2 2017: -$20.67 million | Q3 2017: -$26.07 million | Q1 2018: -$35.44 million | Q2 2018: -$42.74 million | Q3 2018: -$47.94 million | Q1 2019: -$59.86 million | Q2 2019: -$67.49 million | Q3 2019: -$70.85 million | Q1 2020: -$30.88 million | Q2 2020: -$34.76 million | Q3 2020: -$33.32 million | Q1 2021: $14.50 million | Q2 2021: $3.84 million | Q3 2021: $213.0 thousand | Q1 2022: -$7.49 million | Q2 2022: -$9.89 million | Q3 2022: -$11.51 million | Q1 2023: $1.01 million | Q2 2023: $39.00 million | Q3 2023: $38.25 million | Q1 2024: $29.79 million | Q2 2024: $28.58 million | Q3 2024: $32.44 million | Q1 2025: $45.21 million | Q2 2025: $49.90 million | Q3 2025: $52.91 million.
- Over the full 14 years of available data (2012 to 2025), Protalix BioTherapeutics, Inc.'s Stockholders Equity has grown by 1,536.7%.
- Historical annual values: Fiscal year 2025: $48.23 million | Fiscal year 2024: $43.21 million | Fiscal year 2023: $33.57 million | Fiscal year 2022: -$10.64 million | Fiscal year 2021: -$6.04 million | Fiscal year 2020: -$27.04 million | Fiscal year 2019: -$70.32 million | Fiscal year 2018: -$52.88 million | Fiscal year 2017: -$29.46 million | Fiscal year 2016: -$9.96 million | Fiscal year 2015: $10.87 million | Fiscal year 2014: -$55.60 million | Fiscal year 2013: -$26.95 million | Fiscal year 2012: -$3.36 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: